Compare HRMY & ALG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | ALG |
|---|---|---|
| Founded | 2017 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2020 | 1996 |
| Metric | HRMY | ALG |
|---|---|---|
| Price | $36.75 | $147.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $48.08 | ★ $203.50 |
| AVG Volume (30 Days) | ★ 993.4K | 127.6K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | 1.84 | ★ 4.96 |
| Revenue | $868,453,000.00 | ★ $1,603,715,000.00 |
| Revenue This Year | $18.17 | $6.09 |
| Revenue Next Year | $13.71 | $4.51 |
| P/E Ratio | ★ $20.01 | $29.98 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.90 | $133.32 |
| 52 Week High | $43.49 | $219.88 |
| Indicator | HRMY | ALG |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 40.34 |
| Support Level | $36.74 | N/A |
| Resistance Level | $39.40 | $168.92 |
| Average True Range (ATR) | 1.50 | 4.50 |
| MACD | 0.17 | 0.47 |
| Stochastic Oscillator | 80.36 | 59.76 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.